From: Misha Gromov

From: Misha Gromov To: "jeffrey E." <jeevacation®gmail.com> Subject: Re: Date: Sun, 15 May 2016 08:25:07 +0000 50/50 is generous; also will make me more involved if you take it. the erson I s oke to is below is the (rather long) summary/advertisement she sent me on my request We plan to bring to the healthcare market what we call a HealthSpan Pass — an individual recommendation (an individually designed healthcare pathway) on molecular adjustments for healthy ageing and healthspan extension, based on simultaneous analysis of near all molecules (comprising a human metabolome) in a microsample of blood by metabolomics approach being imposed on our academic expertise in molecular metabolism of ageing. In the production workflow we utilise blood metabolomics technology for identification of the molecular changes associated with ageing and biomarkers of age-related disorders. Current and past medicinal interventions, individual lifestyle habits and dietary preferences are also reflected in a molecular composition of blood as a universal metabolic information integrator. From such analysis imposed on our know-why on human molecular metabolism, we are able to determine the impact of particular metabolites on the developmental trajectory of healthy ageing, to diagnose pre-pathological healthspan violations and to indicate the precise molecular targets for personalised fine tuning of ageing metabolism. Additionally, to expand availability of our service and to make it distance- independent, we plan to develop a self-sampling device compatible with our technological metabolomics platform, and to bring it to a medical self-care market as a valuable side product. In the developmental process of our main product HealthSpan Pass, two more add-value side products will be created: UniMetaMarker (universal metabolic biomarker panel) and AgeMetaMarker (healthspan metabolic biomarker panel). A biomarker panel is a set of molecules, selected from human metabolome, with indicative diagnostic properties and a synergistic prognostic power (over an individual biomarker molecule). Our biomarker panels will be utilised for drug discovery, with special emphasis on metabolic disorders. Being particularly targeted on drug discovery for age-associated diseases, we plan to develop the AgeMetaMarker as an integrated blood plasma biomarker panel based on metabolomics of atherosclerosis and cardiovascular disease, cancer, arthritis, osteoporosis, type 2 diabetes, hypertension, Alzheimer's disease and Parkinson's disease, and further aim R&D at improved mechanisms of controlling and combating age-related chronic and metabolic diseases through identification of novel drug targets among the involved molecules. We expect high demand for both biomarker panels - the UniMetaMarker and the AgeMetaMarker - from pharma industry involved in drug development, and special interest to the AgeMetaMarker from those on ageing-related market. Results of our research and development of the UniMetaMarker and the AgeMetaMarker will be utilised in designing of our main product, the HealthSpan Pass - a personalised recommendation for fine tuning of metabolism, based on detection of metabolic alterations critical for healthspan in an individual metabolome. Global health policy disposition. We are going to develop a product for individualised care, which does not exist yet on the market, although there will definitely be a demand for it in line with the Precision Medicine Initiative of the National Institutes of Health (USA) and the Sman Care project (EU). According to NIH, "Precision medicine is an emerging approach for disease treatment and prevention EFTA00641326 that takes into account individual variability in genes, environment, and lifestyle for each person". The Smart Care Project piloted in the first ten EU regions also aims at the individual care to be delivered to older European citizens, with special emphasis on combating threats to independent living and on self-care support. World Health Organization (WHO) in its last year imps= brings healthy ageing into critical focus. In this context of the global healthcare prospects, ow 'HealthSpan Pass' product will provide an individual care pathway for i) healthy ageing and ii) health span extension, based on precise molecular analysis with the metabolomics approach of a self-taken microsample of blood. We put special effort to design the HealthSpan Pass production workflow in a format of a modular element compatible with the developing telehealth infrastructure for distant and self care. Market disposition. Among our possible competitors Metabolon, Inc. is the most developed towards offering an individual metabolomics analysis, however having provided yet only several case studies of personalised metabolomics in close cooperation with and by demand of medical doctors. The main activities of this and other major companies doing commercial metabolomics (like e.g. Iseletanomies Health GmbH) are concentrated mainly around large-scale analytics for pharma industry. As distinct from Metabolon, we from the very beginning aim our business at routinizing diagnostic metabolomics for personalised health care, and go ahead by offering a prognostic metabolomics product for individual health improvement sharpened at ageing and healthspan extension. So, current market disposition makes our product unique and targeted at near future of healthcare industry. Being with our intended HealthSpan Pass product a half-step ahead of the market, we plan fast business growth. Elaborated business development model implies attainment of projected HealthSpan Pass production in a timeframe of 18 to 30 months by the force of 10 to 14 business workers, depending on raised financing. For a quick launch, we have assembled a highly qualified start-up team with German academic (Max Planck Society) and industrial (BASF) biomedical innovation expertise. We plan parallel growth of our business in four main infrastructure directions: • Research & Development of biological markers; two biomarker panels will be developed: UniMetaMarker (universal metabolic biomarker panel as an add-value side product) and AgeMetaMarker (healthspan metabolic biomarker panel) • Technology development — most investment intensive (IP-reach, detailization provided by request), implies: - assembly of metabolite profiling machinery, and - technical development of the device compatible with profiling machinery for self blood collection • Business development (product support program provided by request) • HealthSpan Pass — development of workflow & production With the HealthSpan Pass we dare to define 'Healthy Ageing - Happy Living' as our mission. EFTA00641327 On Fri, 13 May 2016 22:36:14 +0200, jeffrey E. wrote: 1. always , if i invest in something you bring to me. the deal is the same for all my friends. I put up all the money, take all the financial risk , and if there is a profit you and i split it 50/50. 2. I , wrestling with , meaning in a musical phrase. / notes with out a relationship to each other . is composition the arrow on the note category.. can we tell if the string is melodic. does the information in the string somehow give us a window.? repetition. relation. temporal. , absolute number bounds. ? max notes per sec? 3. in your meaning re shape same issue. when is round , round. coarse grain? etc. it appears to me that if something has meaning , that something is bounded. please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA00641328